Collplant biotechnologies announces second quarter financial results for 2023 with revenues of $10.2 million

Received in july 2023, $10 million from partner, abbvie, for achieving a major milestone in the second quarter, for the clinical-phase dermal filler product in accordance with the strategic collaboration agreement entered into collaboration with stratasys, a world-leading 3d printing company, with initial focus on the development of a bioprinting solution for the fabrication of collplant's regenerative breast implants readying breast implant study in large animals for initiation by year end    continued positive sales trajectory for 3d bioinks cash and cash equivalents totaled $22.3 million as of june 30, 2023; cash runway extended with additional $10 million milestone payment received in july 2023 from abbvie revenues of $10.6 million and operating income of $5.7 million for the first six months of 2023 conference call to be held on august 24, 2023 at 10:00 am u.s. et; dial-in information herein rehovot, israel , aug. 24, 2023 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, today announced financial results for the second quarter ended june 30, 2023, and provided a corporate update on its programs. "this quarter, we were very pleased to announce the achievement of an important milestone related to the dermal filler product developed in collaboration with our partner, abbvie, for which we received a $10 million payment.
CLGN Ratings Summary
CLGN Quant Ranking